Altre lingue Spyre Therapeutics, Inc.

Azioni

SYRE

US00773J2024

Biotecnologia

Tempo differito Nasdaq Altri mercati azionari 22:00:00 17/01/2025			Variaz. 5gg	Var. 1 gen.
20,62 ^USD	+0,34%		-8,19%	-11,43%

17/01	I principali ribassisti del mercato	MT
15/01	Wall Street aprirà in forte rialzo mercoledì grazie ai dati positivi sull'inflazione	MT

Altre lingue

Top Premarket Decliners	17/01
Wall Street Set to Open Sharply Higher Wednesday on Positive Inflation Data	15/01
Top Premarket Decliners	15/01
Investors Look Toward Key Inflation Data as US Futures Trend Higher in Premarket	15/01
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE	08/01
Spyre Therapeutics Announces Grants of Inducement Awards	06/01
Spyre Therapeutics Announces Grants of Inducement Awards	03/01
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE	02/01
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE	27/12
Spyre Therapeutics, Inc.(NasdaqGS:SYRE) added to NASDAQ Biotechnology Index	23/12
Spyre Therapeutics Says it will be Added to Nasdaq Biotechnology Index	18/12
Spyre Therapeutics Added to the Nasdaq Biotechnology Index	18/12
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE	04/12
Spyre Therapeutics Announces Grants of Inducement Awards	02/12
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-Life Extended Anti-Tl1a Antibodies	02/12
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE	26/11
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference	25/11
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	19/11
Spyre Therapeutics Prices $200 Million Common Stock Offering	19/11
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock	19/11
Spyre Therapeutics Launching Public Offering of Shares, Warrants	18/11
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants	18/11
Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-47 Antibody for the Treatment of Inflammatory Bowel Disease	13/11
Spyre Therapeutics : Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half Life Extended anti α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing Form 8 K	12/11
Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing	12/11

Iscriviti per accedere a più notizie

Registrazione 100% gratuita

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Spyre Therapeutics, Inc.

Azioni

SYRE

US00773J2024

Biotecnologia

Altre lingue

Filtri